Impact of Bevacizumab on parenchymal damage and functional recovery of the liver in patients with colorectal liver metastases

BACKGROUND: Little is known about the safety of the anti-VEGF antibody bevacizumab in patients undergoing resection for colorectal liver metastases (CLM). This meta-analysis evaluates the impact of bevacizumab on parenchymal damage and functional recovery in patients undergoing resection for CLM. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Volk, Andreas M., Fritzmann, Johannes, Reissfelder, Christoph, Weber, Georg F., Weitz, Jürgen, Rahbari, Nuh N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750178/
https://www.ncbi.nlm.nih.gov/pubmed/26864935
http://dx.doi.org/10.1186/s12885-016-2095-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4750178/
https://www.ncbi.nlm.nih.gov/pubmed/26864935
http://dx.doi.org/10.1186/s12885-016-2095-6

Ejemplares similares